Navigation Links
Arterial in Biological Technology

Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida

... Phase I/II clinical trial in peripheral arterial disease patients and a Phase I trial in patients ... as well as chronic conditions such as peripheral arterial and vascular disease, cardiovascular disease, and ... safety and efficacy study of TSC in peripheral arterial disease patients suffering from intermittent ...

Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant

... of 6R-BH4 in patients with symptomatic peripheral arterial disease (PAD). There was no statistical ... Endothelial dysfunction evaluated by peripheral arterial tonometry in a subset of patients did not show a ... 6R-BH4 was well-tolerated in peripheral arterial disease patients and had a safety profile similar ...

Replidyne and Cardiovascular Systems Sign Merger Agreement

... growth opportunity for treatment of peripheral arterial disease with this product, particularly in ... catheter system for the treatment of peripheral arterial disease, or PAD. PAD affects approximately 8 to ... position the crown at the site of an arterial plaque lesion and remove the plaque by causing ...

HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City

... killers' such as heart disease, stroke, arterial disease and osteoporosis Screenings provide ... the use of the Ankle- Brachial Index. -- arterial Stiffness Index (ASI) Screening -- Also measured ... screening results provide specific data regarding arterial hardening, missed heartbeats, arrhythmias, ...

Old and new therapies combine to tackle atherosclerosis

... stop the growth of tiny blood vessels that feed arterial plaques. Their results suggest that the dual ... reduced blood vessel formation at the site of arterial plaques in experimental rabbits after one week," ... used in the study ate a high-fat diet that caused arterial plaques. The researchers detected new blood ...

Ovalum Ltd. Received Clearance to Market the CiTop™ Product-Line in Israel

... These products are indicated for traversing arterial obstructions, including chronic total occlusions, ... intervention specialists to cross over the arterial blockage in a controllable and reproducible way. ... designed specifically for the most challenging arterial procedures Ovalum Ltd. investors: Ziegler ...

deCODE genetics Announces First Quarter 2008 Financial Results

... development of its leukotriene program. -- arterial thrombosis: DG041. DG041 is deCODE's novel, ... oral anti-platelet therapy for preventing arterial thrombosis without increasing bleeding time. ... and a 20% increase in risk of peripheral arterial disease (PAD), a common and debilitating ...

Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product

... that more than 10 million people have peripheral arterial disease (PAD), AnGes already has completed two ... with critical limb ischemia (advanced peripheral arterial disease) were evaluated for efficacy. The ... AnGes has developed this product for peripheral arterial diseases (ASO and Burger's Disease), which occurs ...

Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting

... Chronic Dialysis Catheter With Patented Triple arterial Lumen Design ... catheter include: - Patented Triple arterial Lumen Design: Ensures functional flow rates ... need for a peel-away sheath. - 360 degree arterial Tip Configuration: Eliminates catheter "side- ...

Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information

... feel that their knowledge of pulmonary arterial hypertension (PAH) and Tracleer have improved due ... treatment PAH. About Tracleer(R) in Pulmonary arterial Hypertension (PAH) Tracleer(R) (bosentan), the ... indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with New ...

Genzyme and Sunway to Collaborate on Gene Therapy Program in China

... in the limbs of patients with peripheral arterial disease. Genzyme is currently conducting a Phase ... claudication, a form of peripheral arterial disease that results in disabling pain or fatigue ... ischemia, a more severe form of peripheral arterial disease that often leads to the need for limb ...

Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007

... from the first 1,500 patients with pulmonary arterial hypertension (PAH) enrolled in the REVEAL(TM) ... in patients with mildly symptomatic pulmonary arterial hypertension Location: Convention Center E266 ... receiving Bosentan therapy for pulmonary arterial hypertension (COMPASS-1) Location: Convention ...

Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease

... revolutionize symptomatic treatment of peripheral arterial disease (PAD). The new Pharmacor report Peripheral arterial Disease finds that Genzyme's HIF-1 alpha therapy ... with Dr. Argent-Katwala regarding the peripheral arterial disease drug market, please visit the Find Out ...

Pulmonary Hypertension Association Names Dr. Nicholas Hill Recipient of 2009 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care

... Center as the recipient of the 2009 PHA Award of Excellence in Pulmonary arterial Hypertension (PAH) Care. The grant, in the amount of $50,000, will be ... receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer(R) through its own subsidiaries in ...

Introducing deCODEme Cardio(TM) and deCODEme Cancer(TM)

... and abdominal aortic aneurysm, stroke and atrial fibrillation, peripheral arterial disease (PAD) and venous thromboempolism. deCODEme Cancer(TM) measures 29 ... DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway ...

Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice

... (a type of white blood cell and part of the body's immune system) to the arterial wall, causing the inflammation that is characteristic of atherosclerosis. ... develop atherosclerosis when fed a high fat diet did not develop chronic arterial inflammation when injected with the mouse version of the CKEY2 peptide. ...

Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008

... to enhance outcomes in patients suffering from lower limb peripheral arterial disease (PAD). The presentation, entitled, "Local Catheter-Directed ... potentially reduce the incidence of restenosis in PAD." About Peripheral arterial Disease Peripheral artery disease, or PAD, is characterized by fatty ...

deCODE genetics Announces Second Quarter 2008 Financial Results

... deCODE. Recent highlights include: Product Development -- DG041 for arterial thrombosis. In June, deCODE announced positive topline results from its ... developed as a next-generation oral anti-platelet therapy for preventing arterial thrombosis without increasing bleeding risk. The prospective, randomized, ...

Ovalum Ltd. Announces Sales Launch of CiTop™ Product-Line in Europe

... The devices are intended to assist in the treatment of chronic complete arterial blockage (CTO). These obstructions are hard to traverse and patients are ... radiology markets designed specifically for the most challenging arterial procedures Ovalum Ltd. investors: Ziegler Meditech equity Partners LP ...

Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008

... and unveiling several new products at AATS: -- Edwards is offering new arterial and venous cannulae, which are the flexible tubes used to establish ... Among these are the FemTrak femoral venous cannula and the OptiSite arterial cannula, which both have proprietary ultra-thin wall technology to ...

Arena Pharmaceuticals Announces First Quarter 2008 Financial Results

... candidate, entered a Phase 2b trial and APD791, our drug candidate for arterial thrombosis, entered a Phase 1b trial," stated Jack Lief, Arena's President ... internally discovered drug candidate intended for the treatment of arterial thrombosis, and initiated a Phase 1b clinical trial to further evaluate ...

A Smoking Gene: deCODE Shows How a Single Variant in the Sequence of the Genome Confers Nicotine Dependence and Risk of Lung Cancer and Other Disease

... increase in risk of lung cancer and a 20% increase in risk of peripheral arterial disease (PAD), a common and debilitating constriction of the arteries to ... 'A variant associated with nicotine dependence, lung cancer and peripheral arterial disease,' is published today in the online edition of Nature, at ...

deCODE Genetics Announces Full-year 2007 Financial Results

... and is presented in the subscriber's secure individual web page. -- arterial thrombosis: DG041. DG041 is deCODE's novel, first-in-class antagonist ... as a next-generation oral anti-platelet therapy for preventing arterial thrombosis without increasing bleeding time. In a Phase II clinical ...

Pathway Medical Technologies Names Paul Buckman Chairman of the Board of Directors

... to design, market and manufacture medical devices for the treatment of arterial disease. The company's initial focus is treating peripheral arterial disease (PAD) more quickly, safely and effectively than existing ...

Clexane(R)/Lovenox(R) Approved in Japan

... important treatment option for millions of patients at risk of VTE(2). In arterial thrombosis, Clexane(R) / Lovenox(R) has demonstrated its effectiveness in ... properties. It is used to inhibit clot formation in venous and arterial vessels to prevent potential acute or chronic complications of venous or ...

LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer

... designs, manufactures, and markets straight and bifurcated polyester arterial prostheses. Polyester vascular grafts are used in a variety of arterial replacement and repair surgeries, predominantly open abdominal aortic ...

deCODE genetics Announces Third Quarter 2007 Financial Results

... its bioequivalence study before the end of this year. -- DG041 for arterial thrombosis. In the past quarter deCODE has successfully completed ... oral anti-platelet therapy -- a mechanism specific means of preventing arterial thrombosis without increasing bleeding time. Clinical studies ...

New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome

... to atherosclerosis or atherothrombosis. The procedure restores coronary arterial flow (or coronary perfusion) in an acutely or sub-acutely occluded artery ... properties. It is used to inhibit clot formation in venous and arterial vessels to prevent potential acute or chronic complications of venous or ...

Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Company's Home Health Care Business

... laboratory studies to provide the most trustworthy continuous noninvasive arterial blood oxygen saturation and pulse rate measurements even under the most ... in outcomes, safety and efficiency by providing accurate measurement of arterial oxygen satuaration and pulse rate and significantly reducing false alarms ...

Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth

... to develop, manufacture and market medical devices for the treatment of arterial disease. The company's initial focus is treating peripheral arterial disease (PAD) more quickly, safely and effectively than existing ...

Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product

... of absorbable biomaterials, which has led to partnerships to commercialize technologies. The Company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc. ...

Burrill & Company Invests in Taiwan Liposome Company

... with advantageous delivery or formulation characteristics. Some of these products include TLC's lead product, ProFlow (used to treat peripheral arterial disease and diabetic neuropathy), which is currently undergoing product development and registration in Asian markets. The company's ovarian and ...

It's Not Just the Sun: deCODE Discovers Sequence Variants Affecting Susceptibility to Skin Cancer

... leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 ...

deCODE Discovers a Gene Linked to Risk of Kidney Stones and Osteoporosis

... leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 ...

deCODE Reinstated to Nasdaq Global Market

... leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 ...

Environmental Tectonics Corporation Announces Additional Hyperbaric Monoplace Chamber Sale to St. John Wound Center

... while fully enclosed in a specially designed chamber at increased atmospheric pressure. HBO is the primary treatment for carbon monoxide poisoning, arterial gas embolism and decompression sickness. It is also used to promote and support healing in the management of conditions in which oxygen transport to ...

Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial

... day mortality was 32% (11/34 patients) in the Toraymyxin(TM) group and 53% (16/30 patients) in the conventional therapy group. - Mean arterial Pressure (MAP) increased (76 to 84 mm Hg; P = 0.001) in the Toraymyxin(TM) group but not in the conventional therapy group (MAP, 74 ...

deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation

... leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 ...

SemBioSys' plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models

... Both experiments confirmed anti-atherosclerotic effects of plant-derived Apo AI(Milano) in the regulation of cholesterol mobilization from the arterial wall, in the lipid content of atherosclerotic plaques, and in the reduction of overall volume of atherosclerotic plaque after multiple injections. ...

deCODE Study Shows Complex Interplay of the Human Biological Clock With Height, Weight and Disease

... leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 ...
Other Contents
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/9/2015)... Calif. , July 9, 2015 /PRNewswire/ ... leading developer of human interface solutions, today ... the industry,s first fully hardware encapsulated fingerprint ... secure authentication technology is literally off the ... and biometric matching within the fingerprint sensor ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
(Date:8/4/2015)... ... August 04, 2015 , ... They say a picture is worth a ... pictures and medical art can be essential. StayWell, a health solutions company, announced today ... Education solutions have been used by physicians and other health care providers for more ...
(Date:8/4/2015)... San Francisco, Calif. (PRWEB) , ... August 04, ... ... services to corporations, law firms and government entities, today announced that John Munro, ... leadership team as Vice President of Managed Services Operations. , “I am thrilled ...
(Date:8/4/2015)... ... August 04, 2015 , ... Patients are ... offered by the world renowned Beverly Hills facelift surgeon , Dr. Paul ... surgery techniques helps individuals to achieve an outer appearance that meets their personal ...
(Date:8/4/2015)... , ... August 04, 2015 , ... T.E.N., an information ... vendor participating in The ISE® Lions’ Den and Jungle Lounge 2015, which will be ... Las Vegas. , During the event, eight emerging security vendors, known as “Gazelles,” will ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... look at unique artistic expressions from a diverse group of exceptionally talented female ... Beautiful Music & Art Festival on September 25-27, 2015 in Downtown Las Vegas. ...
Breaking Medicine News(10 mins):Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 3Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 3Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 2Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 3Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 4Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4
Other TagsOther Tags